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1. Introduction
  Portal hypertension gastropathy (PHG) of cirrhotic has 
become a main clinical manifestations of the decompensated 
cirrhosis in clinical. It threatens life because of the high 
incidence of gastric mucosal bleeding. Omeprazole is one of 
the most common drugs to treat gastric mucosal lesion. Its 
significant inhibition effect on the gastric acid secretion has 
been very clear, but the protective effect on gastric mucosal 
is still unclear. This study is to explore the protective 
effect of omeprazole on gastric mucosal of cirrhotic portal 
hypertension rats, and the possible mechanisms.
2. Materials and methods
2.1. Animals and grouping
  A total of 30 6-week-old male SD rats were selected, 
weighting 200-220 g, which were purchased from 
Experimental Animal Department, XX University. The 
animals were randomly divided into three groups, including 
the normal control group (n=10), cirrhosis group (n=10), 
treatment group (n=10). If rats died or abandoned during 
the study, they were supplemented again. All rats were fed 
by standards pellet then kept under constant humidity and 
temperature 
2.2. Reagents and instruments
  0.03% thioacetamide (TAA), omeprazole capsules 20 mg 
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were purchased from Haikou Qili Pharmaceutical Co., Ltd. 
Rat prostaglandin  E2 (PGE2), tumor necrosis factor-毩 (TNF-
毩) ELISA kit were purchased from Wuhan Boster Reagent 
Company. Optical microscopy, laser doppler flowmeter, 
digital millivoltmeter, electronic scales, micro adding 
sample appliance, etc. were provided by the laboratory.
2.3. Model establishement
  Rats in the normal control group received 25 mg/kg 
ketamine under intraperitoneal anesthesia, draped in a 
sterile manner. They were opened layers by layers and 
the left suprarenal vein was isolated without special 
intervention. After adequate hemostasis, they were sutured 
layers by layers. Animals received water after operation. 
Rats in the cirrhosis group and treatment group underwent 
double ligation after left suprarenal vein fully exposed. If 
there was a branch of small blood vessels, the vessels were 
also ligated together, then were sutured after hemostasis. 
The rats received concentration of 0.03% TAA solution 
as drinking water. Body weight was monitored, and was 
maintained between 200-260 g. If the margin of body weight 
increase was more than 20 g or decrease more than 10 g 
in one week, then concentration of TAA was increased or 
decreased by 50%. All rats were continuously fed for 14 
weeks, then the treatment was stopped for two weeks. After 
three days of molding, the treatment group were fed by 
omeprazole 15 mg/kg • d one time everyday. The sampling 
was performed after 2 weeks.
2.4. Indexes observation
2.4.1. Hemodynamic index detection
  Using laser doppler flowmeter, free portal pressure (FPP), 
portal venous flow (PVF), abdominal aortic pressure (AAP) 
and abdominal aorta blood flow (AAF) at the beginning point 
was measured. Greater and lesser curvatures of gastric 
body, greater and lesser curvatures of gastric antrum on the 
surface of gastric mucosa were also measured. The average 
value were obtained as gastric mucosal blood flow (GMBF).
2.4.2. Glycoprotein (GP) of gastric
  Mucus were scraped on the surface of mucosa in gastric 
gland area and weighed. Glycoprotein content was measured 
by Coomassie brillient blue method.
2.4.3. Basal acid secretion (BAS)
  Gastral cavity was washed with normal saline. The 
beginning part of the duodenum was intubated and the 
duodenum was ligated. One mL/min saline was added with 
uniform injection pump, the remote casing was open once 
every 10 mins for 6 times. H+ concentration was measured by 
0. 2 mol/L NaOH microtitration and the average value were 
obtained.
2.4.4. H+ back diffusion (H+ BD)
  Gastral cavity was washed with sarfeh solution (100 mmol/L 
HCl and 50 mmol/L NaCl). The duodenum was ligated. Sarfeh 
solution was injected at 3 mL/times, 20 min/times for 3 
times. H+ concentration was also measured by microtitration. 
The value was obtained by minusing Sarfeh fluid H+ 
concentration.
2.4.5. Index of gastric mucosal lesion
  Stomach tissue was removed, cut and flatted.The score 
was calculated by Guth standard. Spot-like erosions was 
1, erosion <1 mm was 2, erosion between 1 -2 mm was 3, 
erosion between 2-4 mm was 4, erosion> 4 mm was 5.
2.4.6. Histological observation
  The gastric tissues were fixed, paraffin routinely embedded, 
sectioned, and HE stained. Necrotic status and neutrophil 
infiltration was observed under light microscope, Judgement 
standard was as follows: No necrotic material or neutrophil 
infiltration was 0; A few necrotic material and neutrophil 
infiltration at the bottom edge of the ulcer was 1; Thick 
layer of necrotic at the ulcer floor and obvious neutrophil 
infiltration at the marginal tissue of ulcer was 3; Between 
them was 2.
2.4.7. Serum NO, PGE2, TNF-毩 measurment
  Venous blood samples were collected before the rats were 
sacrificed. After centrifugation, the serum NO content was 
measured. The serum PGE2, TNF-毩 levels were measured 
by radioimmunoassay.
2.5. Statistical analysis
  The data was analyzed with SPSS 13.0 software. Data were 
expressed as mean依SD. Homogeneity of variance was 
carried out for the measurement material, and multiple 
comparison was used if there is significant differences.
P <0.05 was considered as statistical significance.
3. Results
3.1. Mucosa observation
  The gross specimen of gastric in normal control rats 
showed smooth and complete surface. Microscope showed 
glands arranged regularly. Gross specimen of cirrhotic 
rats gastric showed obvious hyperemia and edema, one or 
more strip-shaped erosion and hemorrhagic focus, necrotic 
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material. Microscope showed glandular arranged in disorder, 
great number of neutrophils infiltration, even involving in 
the serous layer. Gross specimen of gastric mucosal in the 
treatment group was with more complete structure. It also 
showed some hemorrhagic spot or hemorrhagic focus, but 
was decreased significantly than that in the cirrhosis group. 
Amount of necrotic material at the bottom of the ulcer was 
also less than that in the cirrhosis group. Microscope showed 
glandular arranged in order, a little neutrophils infiltration 
which was less than that of cirrhosis group.
3.2. Gastric mucosal damage index (GMDI)
  In the control group, there was no damage; the gastric 
mucosal damage index of cirrhotic rats was significantly 
increased. Compared with the control group and treatment 
group, the differences were significant (P<0.05). There was 
still some gastric mucosal injury in the treatment group, 
the damage index was significantly higher than the control 
group (P<0.05) (Table 1).
3.3. Hemodynamic score results
  FPP and AAF index of the cirrhosis group and treatment 
group were significantly higher than that in the control 
group, which indicated successful cirrhosis model. The 
gastric GMBF of the cirrhosis group decreased significantly 
compared with the control group and the treatment group
(P <0.05). The gastric GMBF of the treatment group was 
slightly lower than the normal group, but the difference had 
no statistically significant (P> 0.05) (Table 2).
3.4. Measurement of mucosal glycoproteins and H+
  GP in Cirrhosis group was significantly lower than the 
control group and treatment group (P<0.05). There was no 
significantly difference in BAS secretionamong three groups 
(P> 0.05) (Table 3).
3.5. Serum NO, PGE2, TNF-毩 of humoral factors 
  PGE2 expression in the cirrhosis group and the treatment 
group was decreased significantly compared with that in 
the controls (P<0.05); There was no significantly difference 
between the treatment group and the cirrhosis group 
(P>0.05). TNF-毩 expression in the cirrhosis group was 
significantly increased compared with that in the control 
group and the treatment group, (P<0.05); TNF-毩 expression 
Table 1
Gastric mucosal lesion. 
Groups Number of cases  Damage index Necrotic tissue Infiltration of neutrophils
Control group 10 0 0 0
Cirrhosis group 10 38.5依4.2* 2.8依1.0* 3.4依0.5*
Treatment group 10      8.8依1.1*△    1.3依0.6*△    1.6依0.6*△
Note: * Compared with control group, P <0.05, △ Compared with cirrhosis group, P <0.05.
Table 2
Hemodynamic parameters. 
Groups FPP (kPa) PVF (mL/min) AAP (kPa) AAF (mL/min) GMBF (V/mV)
Control group 0.8依0.2 14.3依2.2 14.3依1.3 37.9依4.3  305.3依22.5
Cirrhosis group 1.5依0.4* 13.2依2.0 15.1依1.0  78.4依7.6*   179.6依18.7*
Treatment group 1.5依0.3* 13.6依2.1 15.3依1.2 79.5依6.8*     288.7依20.1△
Note: * Compared with control group, P <0.05, △ Compared with cirrhosis group, P <0.05.
Table 3
Glycoproteins and H+BD of gastric mucosal.
Groups GP (mg) BAS (毺Eq/ h) H
+BD (毺Eq/h)
Control group 0.4依0.2 10.8依1.1  40.7依4.2
Cirrhosis group  0.2依0.1*   9.8依1.4 133.8依6.9*
Treatment group   0.4依0.2△ 10.3依1.2     44.4依5.6△
Note: * Compared with control group, P <0.05, △ Compared with cirrhosis group, P <0.05.
Table 4
NO, PGE2 and TNF-毩.
Groups Number of cases NO (毺mol/L) PGE2 (mol/L) TNF-毩 (pg/mL)
Control group 10  9.3依2.9 354.8依38.5 0.4依0.1
Cirrhosis group 10 27.6依4.1*  262.4依30.6*  1.7依0.7*
Treatment group 10    40.4依5.3*△  274.2依32.2
*
    1.0依0.3*△
Note: * Compared with control group, P <0.05, △ Compared with cirrhosis group, P <0.05.
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in treatment group was significantly higher than the control 
group (P<0.05). NO expression in the treatment group was 
significantly higher than that in the control group and the 
cirrhotic group (P<0.05); NO expression in the cirrhotic group 
was significantly higher than the control group (P<0.05) 
(Table 4).
4. Discussion
  Cirrhosis is the late stage of various chronic liver diseases, 
portal hypertension is the main manifestation during this 
stage and all the complications have a severe influence 
on patients ‘quality of life. Therefore, it becomes a 
research hotspot to protect the gastric mucosa under portal 
hypertension. According to the previous studies, abundant 
blood flow is the basis for maintaining normal mucosal 
function in the physiological state. After the formation of 
portal hypertension, a large number of visceral blood flow 
through the arteriovenous shunt and collateral circulation 
directly into the systemic circulation, makes mucosal 
capillary network in the ischemic state, which may lead 
to the occurrence of PHG. Omeprazole is one of the most 
important drugs as a proton pump inhibitor, how to reduce 
stomach acid secretion and protect the gastric mucosa 
became the focus of this study.
  To observe whether omeprazole treatment have an impact 
on gastric mucosal ulceration, some studies by established 
an animal model of acute gastric mucosal injury. The result 
showed that omeprazole treatment has an important effect for 
acute gastric mucosal injury, and large doses are better than 
small doses, and that the proton pump inhibitors omeprazole 
can inhibit gastric acid secretion, H+ diffused from gastric 
parietal cells to mucosa significantly reduced, prompting the 
gastric PH value increased significantly. This study suggests 
that H+ BD significantly reduced, which is consistent with the 
above results. Omeprazole can significantly reduce mucosal 
cells acidification damage degree. Meanwhile, the study 
suggests that GP protein was significantly increased. GP as 
a glycoprotein of epithelial cells cover the mucosal surface 
and buffer the mechanical damage between the stomach, 
while also provide the attachment platform for the gastric 
mucosal barrier. It is considered that GP is an accurate and 
sensitive indicator which can reflect the gastric mucosa and 
also play an important role in anti-acid, resisting pepsin 
and prevent ulceration. GP’s increase can help to protect the 
integrity of the gastric mucosa. Studies suggest that during 
gastric mucosal injury, the GP decrease degree is consistent 
with the mucosal injury. Proton pump inhibitor can protect 
mucosa and benefit to the epithelial repair.
  Animal experiments suggested that NO as an important 
radical in the blood can change the gastric mucosal blood 
flow, and the use of NOS inhibitors will increase gastric 
mucosal injury of animal. The increase of serum NO will 
lead to the increase of serum NOS and iNOS, and also 
reduced cNOS, thereby damage to the tissue. But there 
are also studies suggested that after the use of PPI drugs, 
gastric mucosal protective level was positively correlated 
with the NO, considered the mechanism is related to the 
influence of parietal cells H+-K+-ATP activity. This study 
suggests that NO of the omeprazole treatment group was 
significantly higher and the GMBF also increased. Maybe the 
NO vasodilatory effects can promote the increase of GMBF.
Although NO free radical will damage the gastric mucosa 
tissue, NO may mediate the omeprazole‘s protective effect 
on gastric mucosa after omeprazole inhibited  H+-K+-ATP 
enzyme.
  PGE2 is one of the major PGs of gastric, but experiments 
suggest that it can inhibit the apoptosis of rat gastric 
mucosa. It can increase the secretion of gastric epithelial 
mucus and the bicarbonate, also protect gastric mucosa 
to avoid any attack by various invasion factors, and have 
the same damage effect on the acid-ethanol. This study 
suggests that PGE2 significantly lower in cirrhotic rats, but 
the omeprazole treatment did not change significantly. TNF-毩
as one of the inflammatory cytokines can strengthen tail 
lesions by increasing vascular permeability during the 
PHG. Studies suggest that TNF-毩 content was significantly 
associated with the damage degree of toxic mucosal. It 
play an important role as the media factor of endotoxin-
induced gastric mucosal injury, suggested that it can be 
used as early monitoring indicators for the clinical effect of 
gastric mucosal injury. This study suggests that the TNF-
毩 significantly increased in the cirrhosis group, but it can 
be effectively reduced after drug treatment. It may be due 
to the increase of TNF-毩 can increase the local tissue 
inflammation, leading to mucosal ischemia and hypoxia, 
decreased gastric mucosal blood flow and increased blood 
sedimentation, and then increased the damage. This study 
suggests that the damage degree of gastric mucosal surfaces 
can be significantly reduced after omeprazole treatment, 
possibly because of many factors mentioned above.
  In summary, we can speculate that omeprazole play a 
protective role in the gastric mucosa by improving the 
gastric environment, through the influence of inflammatory 
cytokines to slowdown its further damage the gastric mucosa. 
These results suggested that omeprazole have a protective 
effect on the cirrhotic portal hypertension induced gastric 
mucosal injury.
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